Lv3
346 积分 2022-01-22 加入
PDX models for functional precision oncology and discovery science
1天前
已完结
Bystander effect in antibody-drug conjugates: Navigating the fine line in tumor heterogeneity
2天前
已完结
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
16天前
已完结
Development of an ELISA with acidification treatment for an antibody conjugate incorporating Exatecans
18天前
已完结
How the diversity of the faces arises
27天前
已完结
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation
28天前
已完结
Quantifying cell divisions along evolutionary lineages in cancer
30天前
已完结
OA13.02 Global Phase 2 Randomized Trial of BNT327 (Pumitamig; PD-L1 x VEGF-A bsAb) + Chemotherapy for 1L ES-SCLC: Dose Optimization Analysis
1个月前
已关闭
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
1个月前
已完结
Progress in outcomes for patients with metastatic squamous non-small-cell lung cancer
1个月前
已完结
皖公网安备34019202002308
